Inflammation is supposed to solve a problem and then stand down: an infection is controlled, damaged tissue is contained, inflammatory signals decline, and the immune system returns toward baseline. In autoinflammatory disease, the problem is that the machinery built to detect danger can activate too easily, remain active too long, or generate a full inflammatory alarm without the infection or antigen-specific immune target that would normally explain it. In essence, the alarm system itself has become part of the disease.
These conditions are often confused with autoimmune disease because both can produce fatigue, fever, rashes, joint pain, swelling, gastrointestinal symptoms, and injury across multiple organs. This distinction is not absolute, and some diseases involve features of both systems, but the dominant immune disturbance begins in a different place. Autoimmune disease is classically associated with adaptive immunity, involving antigen-specific T cells, B cells, and autoantibodies directed against the body’s own tissues. Autoinflammatory disease is driven primarily by dysregulation of innate immunity, particularly the monocytes, macrophages, neutrophils, cytokines, and intracellular danger sensors responsible for the body’s rapid first response to infection and tissue injury.
The category itself is relatively young. The term autoinflammatory was introduced in 1999 to describe rare inherited periodic-fever syndromes characterized by recurrent systemic inflammation without the high-titer autoantibodies or antigen-specific T cells expected in classical autoimmune disease. Since then, the field has expanded beyond a small group of single-gene disorders to include more complex conditions shaped by combinations of genetic susceptibility, metabolism, cellular stress, environmental triggers, and abnormal innate immune signaling.
At the center of many of these diseases is a basic problem of threat detection. Cells of the innate immune system use receptors to recognize molecular patterns associated with invading microbes, but they also respond to internal danger signals released by damaged or metabolically stressed cells. Some of those signals promote the assembly of inflammasomes, intracellular protein complexes that convert cellular disturbance into inflammatory action. The best studied is the NLRP3 inflammasome, which activates caspase-1, promotes the maturation and release of interleukin-1β and interleukin-18, and can trigger an inflammatory form of cell death called pyroptosis. In this way, a disturbance inside the cell becomes a signal capable of recruiting and amplifying inflammation throughout the surrounding tissue.
That system is protective when a real threat has to be contained. The trouble begins when the activation threshold becomes too low or the signal fails to resolve. In gout, for example, monosodium urate crystals act as internal danger signals that activate NLRP3 and drive the caspase-1-dependent release of IL-1β and IL-18. Different diseases may begin with different triggers, but they can converge on the same outcome: innate immune cells repeatedly receiving the biochemical message that the body is in danger. Pyroptotic cells can then release additional inflammatory material, damaged mitochondria can generate more stress signals, and cytokines can recruit further immune activity. What began as threat detection can become a self-reinforcing cycle.
The prevalence of several autoinflammatory diseases is increasing worldwide. The estimated number of people living with gout worldwide increased from 22.3 million in 1990 to 56.5 million in 2021, while the age-standardized prevalence rose from approximately 537 to 654 cases per 100,000 people. Psoriasis, an immune-mediated disease with both innate and adaptive components, increased from an estimated 23.1 million cases in 1990 to 43.0 million in 2021, accompanied by an increase in age-standardized prevalence from approximately 478 to 516 cases per 100,000. Global inflammatory bowel disease cases also rose from approximately 2.17 million to 3.83 million over the same period, although its age-standardized prevalence declined, showing that population growth and aging account for part of the expanding headcount. Although psoriasis and inflammatory bowel disease are not classic autoinflammatory syndromes, they are relevant here because innate immune activation, cellular stress, and inflammasome-related pathways contribute to their biology.
Molecular hydrogen (H₂) becomes relevant here because, while it is being studied for its ability to reduce inflammation, it does not indiscriminately block the immune system. Instead, the available evidence suggests that it acts on the cellular disturbances that intensify inflammatory signaling, including mitochondrial dysfunction, excessive reactive oxygen species (ROS), oxidized mitochondrial DNA, impaired removal of damaged cellular components, and disrupted stress-response pathways. These signals are useful when they indicate genuine infection or tissue injury, but they become harmful when damaged or stressed cells continue presenting the innate immune system with evidence of danger. By reducing the accumulation and inflammatory interpretation of those signals, molecular hydrogen may help limit excessive inflammation without broadly disabling the immune functions required for defense and repair. Its proposed role is therefore not to switch inflammation off, but to reduce the cellular pressure that keeps turning it back on.
This proposed mechanism aligns closely with the biology of autoinflammatory disease. In macrophages exposed to lipopolysaccharide, molecular hydrogen reduced mitochondrial ROS, the formation of oxidized mitochondrial DNA, and the interaction of that damaged DNA with NLRP3, thereby suppressing inflammasome activation. In a sepsis model, molecular hydrogen promoted autophagy, the cellular process used to remove damaged components, while reducing mitochondrial dysfunction, NLRP3 activation, cytokine release, and organ injury. Another study using Nrf2-knockout mice found that molecular hydrogen’s effects on NLRP3, caspase-1, IL-1β, IL-18, mitochondrial function, and neurological injury depended substantially on Nrf2, a transcription factor involved in endogenous antioxidant and cellular-defense responses.
Newer research suggests that the interaction may extend beyond conventional antioxidant signaling. In a 2026 ulcerative colitis study combining human tissue, cultured colonic epithelial cells, and a mouse model, molecular hydrogen increased the lactylation of the metabolic enzyme PKM2, strengthened its interaction with NLRP3, and reduced inflammasome activation, pyroptosis, inflammatory cytokine release, and intestinal injury. Separate work in a psoriasis model found that molecular hydrogen reduced ROS, inflammatory cytokines, keratinocyte proliferation, and activation of the cGAS–STING pathway, another innate sensing system that responds to misplaced or damaged DNA. The emerging possibility is that molecular hydrogen changes how cells interpret stress, damaged DNA, metabolic disruption, and mitochondrial dysfunction before those signals are converted into sustained immune activation.
However, human clinical evidence lags behind mechanistic evidence. A parallel-controlled study reported improvement in psoriasis severity and itching after eight weeks of hydrogen-water bathing. A randomized, double-blind trial of hydrogen inhalation in ulcerative colitis reported improvements in the intestinal microbiome. Finally, an individual clinical report described improvement in Behçet’s disease ulcers and skin lesions following the use of hydrogen-rich water.
The distinction between mechanism and treatment is therefore essential. Cell and animal studies can show that molecular hydrogen interacts with pathways relevant to autoinflammation, but they cannot show that it controls a chronic human disease. The available clinical studies are small, involve different conditions and delivery methods, and largely concern diseases with mixed autoinflammatory and autoimmune features rather than well-defined hereditary autoinflammatory syndromes. There is not yet enough evidence to determine which patients might respond, what dose or delivery method would be appropriate, how long an intervention would need to continue, or whether any biological changes would translate into durable control of disease activity.
However, the available evidence strongly suggests that H₂ repeatedly intersects with the biology that allows inflammatory alarms to escalate: mitochondrial ROS, oxidized mitochondrial DNA, impaired autophagy, NLRP3 activation, inflammatory cytokine maturation, pyroptosis, and other intracellular danger-sensing pathways. That pattern is mechanistically coherent even though its clinical significance remains uncertain. Molecular hydrogen should therefore be considered an experimental adjunct rather than an alternative to disease-specific medical care. Its value, should it be confirmed, may not come from broadly suppressing immunity, but from helping stressed cells generate fewer of the signals that keep innate immunity activated. That possibility now requires controlled trials in clearly defined patient populations, with meaningful measures of symptoms, inflammatory activity, medication use, disease flares, and long-term safety.
References
· Broderick, L., & Hoffman, H. M. (2022). IL-1 and autoinflammatory disease: biology, pathogenesis and therapeutic targeting. Nature reviews. Rheumatology, 18(8), 448–463. https://doi.org/10.1038/s41584-022-00797-1
· Chen, H., Mao, X., Meng, X., Li, Y., Feng, J., Zhang, L., Zhang, Y., Wang, Y., Yu, Y., & Xie, K. (2019). Hydrogen alleviates mitochondrial dysfunction and organ damage via autophagy‑mediated NLRP3 inflammasome inactivation in sepsis. International journal of molecular medicine, 44(4), 1309–1324. https://doi.org/10.3892/ijmm.2019.4311
· Grateau, G., Hentgen, V., Stojanovic, K. S., Jéru, I., Amselem, S., & Steichen, O. (2013). How should we approach classification of autoinflammatory diseases?. Nature reviews. Rheumatology, 9(10), 624–629. https://doi.org/10.1038/nrrheum.2013.101
· Guan, C., Zhang, Z., Wang, L., Chen, S. A., & Luo, X. (2024). Successful treatment of Behçet's disease ulcers and skin lesions with hydrogen water. International journal of dermatology, 63(3), 379–380. https://doi.org/10.1111/ijd.16958
· Jin, J., Yue, L., Du, M., Geng, F., Gao, X., Zhou, Y., Lu, Q., & Pan, X. (2025). Molecular Hydrogen Therapy: Mechanisms, Delivery Methods, Preventive, and Therapeutic Application. MedComm, 6(5), e70194. https://doi.org/10.1002/mco2.70194
· Krainer, J., Siebenhandl, S., & Weinhäusel, A. (2020). Systemic autoinflammatory diseases. Journal of autoimmunity, 109, 102421. https://doi.org/10.1016/j.jaut.2020.102421
· Li, M., Nie, Q., Xia, Q., & Jiang, Z. (2025). Assessing cross-national inequalities and predictive trends in gout burden: a global perspective (1990-2021). Frontiers in medicine, 12, 1527716. https://doi.org/10.3389/fmed.2025.1527716
· Li, Q., Kou, Y., Zhang, M., Wu, C., Mi, R., Jiang, W., Cheng, Y., Ge, L., Yang, K., Huang, Z., Tian, Y., Luo, B., Ha, Y., Yin, W., Guo, W., Zhu, W., Liu, J., Ye, S., Weng, Y., Wu, J., … Yang, Y. (2026). Sex-specific and socioeconomic disparities in the global burden of inflammatory bowel disease in 204 countries, 1990-2021: projections to 2050. Frontiers in immunology, 16, 1673212. https://doi.org/10.3389/fimmu.2025.1673212
· Maruyama, T., Ishikawa, D., Kurokawa, R., Masuoka, H., Nomura, K., Haraikawa, M., Orikasa, M., Odakura, R., Koma, M., Omori, M., Ishino, H., Ito, K., Shibuya, T., Suda, W., & Nagahara, A. (2025). Hydrogen Gas Inhalation Improved Intestinal Microbiota in Ulcerative Colitis: A Randomised Double-Blind Placebo-Controlled Trial. Biomedicines, 13(8), 1799. https://doi.org/10.3390/biomedicines13081799
· Ren, J. D., Wu, X. B., Jiang, R., Hao, D. P., & Liu, Y. (2016). Molecular hydrogen inhibits lipopolysaccharide-triggered NLRP3 inflammasome activation in macrophages by targeting the mitochondrial reactive oxygen species. Biochimica et biophysica acta, 1863(1), 50–55. https://doi.org/10.1016/j.bbamcr.2015.10.012
· Savic, S., Caseley, E. A., & McDermott, M. F. (2020). Moving towards a systems-based classification of innate immune-mediated diseases. Nature reviews. Rheumatology, 16(4), 222–237. https://doi.org/10.1038/s41584-020-0377-5
· Schlesinger, N., & Kaufmann, D. (2026). Is Gout an Autoinflammatory Disease?. Current rheumatology reports, 28(1), 9. https://doi.org/10.1007/s11926-026-01216-0
· Szekanecz, Z., McInnes, I. B., Schett, G., Szamosi, S., Benkő, S., & Szűcs, G. (2021). Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases. Nature reviews. Rheumatology, 17(10), 585–595. https://doi.org/10.1038/s41584-021-00652-9
· van Kempen, T. S., Wenink, M. H., Leijten, E. F., Radstake, T. R., & Boes, M. (2015). Perception of self: distinguishing autoimmunity from autoinflammation. Nature reviews. Rheumatology, 11(8), 483–492. https://doi.org/10.1038/nrrheum.2015.60
· Wu, Y., Wang, X., Sun, Y., Duan, Y., Zhang, M., Sang, H., Yu, P., & Kong, Q. (2026). Hydrogen ameliorates psoriasis-like skin inflammation via inhibiting the cGAS-STING pathway. Clinical and experimental immunology, 220(1), uxaf081. https://doi.org/10.1093/cei/uxaf081
· Xie, K., Zhang, Y., Wang, Y., Meng, X., Wang, Y., Yu, Y., & Chen, H. (2020). Hydrogen attenuates sepsis-associated encephalopathy by NRF2 mediated NLRP3 pathway inactivation. Inflammation research : official journal of the European Histamine Research Society ... [et al.], 69(7), 697–710. https://doi.org/10.1007/s00011-020-01347-9
· Xiong, J., Xue, T., Tong, M., Xu, L., & Bai, B. (2025). Dynamic trend analysis of global psoriasis burden from 1990 to 2021: a study of gender, age, and regional differences based on GBD 2021 data. Frontiers in public health, 13, 1518681. https://doi.org/10.3389/fpubh.2025.1518681
· Yang, T., Lu, F., Kang, Y., Wang, L., Li, M., Xu, W., Bai, S., Yu, Y., Shi, Y., & Qin, H. (2026). Molecular hydrogen suppresses gut inflammation and pyroptosis in ulcerative colitis through promoting PKM2 lactylation to block NLRP3 inflammasome activation. International immunopharmacology, 180, 116726. https://doi.org/10.1016/j.intimp.2026.116726
· Zhu, Q., Wu, Y., Li, Y., Chen, Z., Wang, L., Xiong, H., Dai, E., Wu, J., Fan, B., Ping, L., & Luo, X. (2018). Positive effects of hydrogen-water bathing in patients of psoriasis and parapsoriasis en plaques. Scientific reports, 8(1), 8051. https://doi.org/10.1038/s41598-018-26388-3